Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 26.8% in December

Capricor Therapeutics Inc (NASDAQ:CAPR) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 5,590,000 shares, an increase of 26.8% from the November 30th total of 4,410,000 shares. Based on an average trading volume of 3,570,000 shares, the days-to-cover ratio is currently 1.6 days.

Capricor Therapeutics Price Performance

CAPR remained flat at $14.08 during trading hours on Friday. The company had a trading volume of 774,032 shares, compared to its average volume of 1,193,585. The business’s fifty day moving average is $17.36 and its 200-day moving average is $10.60. The stock has a market capitalization of $640.22 million, a price-to-earnings ratio of -13.28 and a beta of 3.98. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of CAPR. Main Street Financial Solutions LLC increased its stake in shares of Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after acquiring an additional 7,500 shares during the period. SG Americas Securities LLC bought a new position in Capricor Therapeutics during the 3rd quarter valued at $133,000. Rhumbline Advisers bought a new position in Capricor Therapeutics during the 2nd quarter valued at $147,000. The Manufacturers Life Insurance Company acquired a new position in shares of Capricor Therapeutics during the 3rd quarter valued at $161,000. Finally, Sassicaia Capital Advisers LLC bought a new stake in shares of Capricor Therapeutics in the 3rd quarter worth $192,000. Institutional investors own 21.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on CAPR shares. Piper Sandler initiated coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Thursday, November 14th. Cantor Fitzgerald boosted their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Finally, Maxim Group boosted their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat.com, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.